Developer docs
API playgroundTry for free, no card

Search company profiles

ImpriMed

Full company profile

uuid0000cia

Namestring
ImpriMed
Legal namestring
ImpriMed, Inc.
Company typeenum
Private
Founded yearint
2017
Descriptiontext

ImpriMed, Inc. is a privately held, AI-driven precision medicine company headquartered in Palo Alto, California, with a regional presence in Seoul, South Korea through ImpriMed Korea. Founded in 2017, the company combines a proprietary robotic ex vivo live-cell drug sensitivity assay with multimodal machine learning models trained on a 2,500+ canine patient outcomes database to predict response to 13 anticancer drugs and CHOP combination therapy for canine and feline lymphoma and leukemia. Its veterinary product portfolio is anchored by the Personalized Prediction Profile (PPP) flagship service and includes a la carte offerings — Drug Response Predictions, Immunoprofile, Flow Cytometry, PARR clonality testing, MDR1 genotyping, and digital cytology — with parallel feline-specific variants. Services are delivered in 3-7 days through an A2LA-accredited US lab (Certificate #5664.01), a proprietary Vet Portal, and FedEx overnight shipping with proprietary transport media.

The company operates three business lines: (1) per-test veterinary service fees to 300+ veterinary oncologists across 340+ collaborating hospitals (primarily US, with Korea via ImpriMed Korea), with quote-based pricing not publicly disclosed; (2) ex vivo CRO services for pharmaceutical and biotech customers, sold via a proposal-based enterprise motion for studies in AML, multiple myeloma, pancreatic cancer, and non-Hodgkin lymphoma; and (3) human precision medicine, planned for 2026 launch on the xCellSense platform as a research/investigational-use predictive service for human hematologic cancers. Revenue mechanics blend per-test transactional fees, multi-year CRO contracts, and a planned professional services stream in human oncology.

ImpriMed has raised approximately $34.7 million across five funding rounds (most recently a $23 million Series A in November 2023 led by SBVA) and operates with 11-50 employees. Recent strategic moves include the appointment of a Chief Commercial Officer in October 2025, relocation to a new Palo Alto laboratory, and selection for an oral presentation at the 2025 American Society of Hematology Annual Meeting. The company's academic and ecosystem footprint includes 17 peer-reviewed publications, Mayo Clinic Platform AI Accelerator alumni status, and ongoing conference presence at ASH, ASCO, VCS, ACVIM, and AACR.

Short descriptiontext

ImpriMed is an AI-driven precision medicine company that uses proprietary live-cell drug sensitivity testing and multimodal machine learning to predict anticancer drug responses for canine and feline lymphoma and leukemia, serving 300+ veterinary oncologists across 340+ hospitals while expanding into pharmaceutical CRO services and human oncology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug response prediction, veterinary oncology diagnostics, precision medicine services, ex vivo CRO services, canine lymphoma testing
Industry2 codes
PRIMARYHLAMADAA
Reference Laboratory Testing (Clinical Pathology & Chemistry)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Diagnostics (Labs & Imaging)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)
NAICS code2 codes
  • Veterinary Services54194
  • Medical Laboratories621511
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Veterinary Diagnostics
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Per-test veterinary service fees
TypeTransaction Fee
Description

Per-order service fees for canine and feline diagnostic and predictive services: Personalized Prediction Profile (PPP), Drug Response Predictions, Immunoprofile, Flow Cytometry only, PARR only, MDR1 genotyping, and cytology; prices are quote-based and not publicly disclosed, with services ordered through the Vet Portal after vet onboarding.

imprimedicine.com
2Ex vivo CRO services for pharma and biotech
TypeProfessional Services
Description

Contract research / professional services revenue from pharmaceutical and biotech customers using ImpriMed's live-cell-based predictive analytics to accelerate oncology pipelines (e.g., AML, multiple myeloma, pancreatic cancer, non-Hodgkin lymphoma); engagements initiated via a Request a Proposal flow.

imprimedicine.com
3Human precision medicine research services
TypeProfessional Services
Description

Planned expansion into human precision medicine by 2026, offering research and investigational-use predictive services for AML and other hematologic malignancies using the xCellSense platform (revenue model currently research/collaboration-oriented, not yet a commercial diagnostic).

prnewswire.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure, Others
Pricing details2 tiers
1Per-order veterinary service fees (quote-based)
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed; quotes provided within 1 business day via sales@imprimedicine.com. Retail price for pet parents varies depending on the veterinarian.

imprimedicine.com
2CRO services for pharma (proposal-based)
ModelOtherBilling cadenceMulti-year contract
Notes

Engagement scoped via "Request a Proposal" on the CRO page; pricing tailored to project scope (live-cell-based predictive analytics, AML, MM, pancreatic, NHL studies).

imprimedicine.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1xCellSense platform
Description

ImpriMed's proprietary platform used for ex vivo drug sensitivity testing combined with genomic profiling to predict clinical responses and identify synergistic drug combinations in oncology research, including acute myeloid leukemia.

prnewswire.com
Core offering1 text field

ImpriMed provides AI-driven precision medicine services that predict anticancer drug response for individual veterinary and human oncology patients. Its core offering is a laboratory-based diagnostic and predictive service (centered on the Personalized Prediction Profile) that combines live-cell drug sensitivity testing, flow cytometry, and PARR clonality testing with proprietary multimodal AI models trained on thousands of real-world canine patient outcomes. The company also sells contract research services (Ex Vivo CRO Services for Pharma) using its xCellSense platform to accelerate pharmaceutical oncology pipelines.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

ImpriMed offers a single integrated AI-driven precision medicine platform with distinct service lines for veterinary (canine and feline), human oncology, and pharmaceutical CRO use. The veterinary offering is built around the Personalized Prediction Profile (PPP) flagship service, which combines live-cell drug sensitivity testing, flow cytometry, PARR clonality testing, and proprietary AI models trained on 2,500+ canine patient outcomes to predict response to 13 anticancer drugs and CHOP combination therapy. Supporting modules — Drug Response Predictions, Immunoprofile, Flow Cytometry, PARR, MDR1 Genotyping, and Digital Cytology — can be ordered individually or bundled within the PPP, with parallel feline-specific variants of Immunoprofile, Flow Cytometry, and PARR. The xCellSense platform extends the same ex vivo drug sensitivity testing approach to human hematologic cancers (AML, ALL, multiple myeloma, non-Hodgkin lymphoma). The Ex Vivo CRO Services for Pharma arm offers live-cell-based analytics to pharmaceutical companies to accelerate oncology pipelines, and the Veterinary Cancer Pioneers Podcast serves as a brand content channel.

Product and service12 records
1Personalized Prediction Profile (PPP)
CategoryVeterinary precision medicine diagnostic service
Description

AI-driven drug response prediction service for canine lymphoma and leukemia that combines live-cell drug sensitivity testing, flow cytometry, and PARR clonality testing with proprietary AI models to predict response to 13 anticancer drugs and CHOP combination therapy. For board-certified veterinary oncologists and their canine patients, with 7-day turnaround.

2Drug Response Predictions
CategoryVeterinary precision medicine diagnostic service
Description

Standalone AI-driven anticancer drug selection service for canine patients using ImpriMed's live-cell drug sensitivity testing platform, providing personalized drug response predictions without the full Immunoprofile component. For veterinary oncologists.

3Canine Immunoprofile
CategoryVeterinary diagnostic service
Description

Canine diagnostic support service combining flow cytometry and PARR testing to subtype lymphoma/leukemia and provide prognostic information. For veterinary oncologists.

4Canine Flow Cytometry
CategoryVeterinary diagnostic service
Description

Canine flow cytometry service that determines lymphoma or leukemia subtypes by quantifying levels of 10 antigens (CD21, CD79a, CD3, CD4, CD8, CD5, CD45, CD34, CD14, MHC class II) on patient tumor cells. For veterinary oncologists.

5Canine PARR (PCR for Antigen Receptor Rearrangement)
CategoryVeterinary diagnostic service
Description

Canine PCR-based clonality test that detects neoplastic B-cell or T-cell clones by amplifying the VJ region of the immunoglobulin heavy chain gene and a region in the T-cell receptor gamma chain gene, helping discriminate lymphoma from reactive or inflammatory conditions. For veterinary oncologists.

6Multidrug Sensitivity Genotyping (MDR1)
CategoryVeterinary diagnostic service
Description

Canine genetic test that identifies MDR1 carrier status to predict drug sensitivity and help avoid adverse drug reactions. For veterinary oncologists.

7Digital Cytology
CategoryVeterinary diagnostic service
Description

Cytology confirmation service for lymphoma or leukemia diagnosis with digital analysis. For veterinary oncologists.

8Feline Immunoprofile
CategoryVeterinary diagnostic service
Description

Feline-specific diagnostic support service combining PARR and flow cytometry for lymphoma/leukemia subtype diagnosis, including cell-sizing data for high-accuracy feline lymphoma characterization. For veterinary oncologists treating feline patients.

9Feline Flow Cytometry
CategoryVeterinary diagnostic service
Description

Feline-specific flow cytometry service for accurate lymphoma or leukemia subtype determination. For veterinary oncologists treating feline patients.

10Feline PARR
CategoryVeterinary diagnostic service
Description

Feline-specific PCR for Antigen Receptor Rearrangement assay with high-specificity detection of clonal neoplasia and B-cell/T-cell clonality testing, returning cell sizing and immunophenotyping results in 3-4 calendar days. For veterinary oncologists treating feline patients.

11Ex Vivo CRO Services for Pharma
CategoryContract research organization service
Description

Contract research organization service offering live-cell-based predictive analytics to accelerate pharmaceutical and biotech oncology pipelines, with ex vivo drug sensitivity testing on patient-derived cancer cells across programs such as AML, multiple myeloma, pancreatic cancer, and non-Hodgkin lymphoma. For pharmaceutical and biotechnology companies.

12Human Precision Medicine (xCellSense Platform)
CategoryHuman precision medicine service
Description

AI-driven precision medicine service for human oncology that uses the xCellSense platform to combine ex vivo drug sensitivity testing with genomic profiling to predict patient-specific drug responses and identify synergistic drug combinations, with research and investigational use in AML, ALL, multiple myeloma, and non-Hodgkin lymphoma. For academic translational researchers, hematologist-oncologists, and pharmaceutical partners.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

ImpriMed was one of 7 startups selected for the Mayo Clinic AI Accelerator (per MedCity News 2022 coverage referenced on ImpriMed's homepage). The accelerator supports validation and scaling of ImpriMed's AI platform in a clinical environment.

Strategic tierCoreTypeTechnology or Integration
Description

Stripe is ImpriMed's third-party payment processor for veterinary clinic transactions; ImpriMed does not store any card payment data, and all Stripe-collected data is subject to Stripe's privacy notice.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

ImpriMed provides prepaid FedEx shipping labels and boxes to veterinary clinics to enable overnight delivery of live tumor and blood samples to its Palo Alto lab; central to the live-cell assay workflow.

4American Association for Laboratory Accreditation (A2LA)
Strategic tierCoreTypeOthers
Description

A2LA accredits ImpriMed's US laboratory under Certificate #5664.01 for canine lymphoma/leukemia PARR clonality testing, flow cytometry immunophenotyping, MDR1 genotyping, and feline PARR/flow cytometry services.

imprimedicine.com
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

FidoCure offers precision medicine and genetic testing for canine cancer, directly overlapping ImpriMed's veterinary oncology positioning. Both companies target veterinary oncologists with AI-driven drug selection tools for dogs with cancer.

2Vidium Animal Health
TypeDirect peer
Description

Vidium provides precision medicine diagnostics and genomic testing for veterinary cancer patients. It is a direct competitor in the veterinary oncology precision diagnostics space, serving the same board-certified oncologist customer base as ImpriMed.

TypeEmerging player
Description

PetDx develops liquid biopsy and multi-cancer early detection tests for dogs using next-generation sequencing. While focused on detection rather than drug response prediction, it competes for the same veterinary oncology budget and clinical workflow slot as ImpriMed.

TypeBroad incumbent
Description

IDEXX is the dominant veterinary diagnostics company, offering reference lab services across many species and analytes. It is a broad incumbent whose reference lab and specialty offerings overlap with ImpriMed's veterinary diagnostic services, though IDEXX does not focus specifically on AI-driven oncology drug response prediction.

TypeBroad incumbent
Description

Antech is a large veterinary reference laboratory network owned by Mars Petcare, offering broad diagnostic panels including oncology. It competes with ImpriMed for veterinary clinic reference lab spend, though its AI-driven lymphoma drug response prediction capability is not a comparable focus.

6Tempus AI
TypeBroad incumbent
Description

Tempus is a leading human precision medicine company using AI and multi-modal data (genomics, imaging, clinical) to support oncology decision-making. It is relevant as ImpriMed's reference point for scaling its xCellSense human precision medicine platform.

TypeEmerging player
Description

Personalis provides genomics-based precision oncology services for biopharma and clinicians, with a focus on minimal residual disease and tumor profiling. Comparable to ImpriMed's pharma CRO arm and its planned human oncology expansion via multi-omic AI.

8Notable Labs
TypeEmerging player
Description

Notable Labs offers ex vivo drug sensitivity testing for cancer patients using automated platforms to predict treatment response. It is a direct comparable to ImpriMed's ex vivo CRO offering and xCellSense platform, especially in hematologic malignancies.

TypeEmerging player
Description

Embark provides dog DNA and genetic health testing, including MDR1 and breed-related risk screening. It overlaps with ImpriMed's MDR1 genotyping and precision veterinary positioning but targets a broader pet-owner consumer audience.

TypeBroad incumbent
Description

Guardant Health is a leading liquid biopsy and precision oncology company focused on human cancer. It is a broad incumbent relevant to ImpriMed's human oncology roadmap, particularly as a comparator on data scale and pharma partnership economics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors29 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ImpriMed

Veterinary Diagnosticsimprimedicine.com

ImpriMed is an AI-driven precision medicine company that uses proprietary live-cell drug sensitivity testing and multimodal machine learning to predict anticancer drug responses for canine and feline lymphoma and leukemia, serving 300+ veterinary oncologists across 340+ hospitals while expanding into pharmaceutical CRO services and human oncology.

What ImpriMed does

ImpriMed, Inc. is a privately held, AI-driven precision medicine company headquartered in Palo Alto, California, with a regional presence in Seoul, South Korea through ImpriMed Korea. Founded in 2017, the company combines a proprietary robotic ex vivo live-cell drug sensitivity assay with multimodal machine learning models trained on a 2,500+ canine patient outcomes database to predict response to 13 anticancer drugs and CHOP combination therapy for canine and feline lymphoma and leukemia. Its veterinary product portfolio is anchored by the Personalized Prediction Profile (PPP) flagship service and includes a la carte offerings — Drug Response Predictions, Immunoprofile, Flow Cytometry, PARR clonality testing, MDR1 genotyping, and digital cytology — with parallel feline-specific variants. Services are delivered in 3-7 days through an A2LA-accredited US lab (Certificate #5664.01), a proprietary Vet Portal, and FedEx overnight shipping with proprietary transport media.

The company operates three business lines: (1) per-test veterinary service fees to 300+ veterinary oncologists across 340+ collaborating hospitals (primarily US, with Korea via ImpriMed Korea), with quote-based pricing not publicly disclosed; (2) ex vivo CRO services for pharmaceutical and biotech customers, sold via a proposal-based enterprise motion for studies in AML, multiple myeloma, pancreatic cancer, and non-Hodgkin lymphoma; and (3) human precision medicine, planned for 2026 launch on the xCellSense platform as a research/investigational-use predictive service for human hematologic cancers. Revenue mechanics blend per-test transactional fees, multi-year CRO contracts, and a planned professional services stream in human oncology.

ImpriMed has raised approximately $34.7 million across five funding rounds (most recently a $23 million Series A in November 2023 led by SBVA) and operates with 11-50 employees. Recent strategic moves include the appointment of a Chief Commercial Officer in October 2025, relocation to a new Palo Alto laboratory, and selection for an oral presentation at the 2025 American Society of Hematology Annual Meeting. The company's academic and ecosystem footprint includes 17 peer-reviewed publications, Mayo Clinic Platform AI Accelerator alumni status, and ongoing conference presence at ASH, ASCO, VCS, ACVIM, and AACR.

ImpriMed firmographics

Firmographics
Name
ImpriMed
Legal name
ImpriMed, Inc.
Website
https://imprimedicine.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
ImpriMed is an AI-driven precision medicine company that uses proprietary live-cell drug sensitivity testing and multimodal machine learning to predict anticancer drug responses for canine and feline lymphoma and leukemia, serving 300+ veterinary oncologists across 340+ hospitals while expanding into pharmaceutical CRO services and human oncology.
Ownership category
akta.pro rank

ImpriMed industry classification

Industry
Product category
Veterinary Diagnostics
NAICS
Veterinary Services (54194), Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAMADAA
Reference Laboratory Testing (Clinical Pathology & Chemistry)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Diagnostics (Labs & Imaging)
SECONDARYHLAAANAF
Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics)

Keywords

  • AI drug response prediction
  • Veterinary oncology diagnostics
  • Precision medicine services
  • Ex vivo CRO services
  • Canine lymphoma testing

Where ImpriMed is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices3 records

Markets served

ImpriMed business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure, Others

Revenue model

  1. Per-test veterinary service fees: Per-order service fees for canine and feline diagnostic and predictive services: Personalized Prediction Profile (PPP), Drug Response Predictions, Immunoprofile, Flow Cytometry only, PARR only, MDR1 genotyping, and cytology; prices are quote-based and not publicly disclosed, with services ordered through the Vet Portal after vet onboarding.
  2. Ex vivo CRO services for pharma and biotech: Contract research / professional services revenue from pharmaceutical and biotech customers using ImpriMed's live-cell-based predictive analytics to accelerate oncology pipelines (e.g., AML, multiple myeloma, pancreatic cancer, non-Hodgkin lymphoma); engagements initiated via a Request a Proposal flow.
  3. Human precision medicine research services: Planned expansion into human precision medicine by 2026, offering research and investigational-use predictive services for AML and other hematologic malignancies using the xCellSense platform (revenue model currently research/collaboration-oriented, not yet a commercial diagnostic).

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goPer-order veterinary service fees (quote-based)
OtherMulti-year contractCRO services for pharma (proposal-based)

Go-to-market motion4 records

Distribution channels4 records

Marketing channels8 records

ImpriMed product offering

Product offering

Core offering

ImpriMed provides AI-driven precision medicine services that predict anticancer drug response for individual veterinary and human oncology patients. Its core offering is a laboratory-based diagnostic and predictive service (centered on the Personalized Prediction Profile) that combines live-cell drug sensitivity testing, flow cytometry, and PARR clonality testing with proprietary multimodal AI models trained on thousands of real-world canine patient outcomes. The company also sells contract research services (Ex Vivo CRO Services for Pharma) using its xCellSense platform to accelerate pharmaceutical oncology pipelines.

Product overview

ImpriMed offers a single integrated AI-driven precision medicine platform with distinct service lines for veterinary (canine and feline), human oncology, and pharmaceutical CRO use. The veterinary offering is built around the Personalized Prediction Profile (PPP) flagship service, which combines live-cell drug sensitivity testing, flow cytometry, PARR clonality testing, and proprietary AI models trained on 2,500+ canine patient outcomes to predict response to 13 anticancer drugs and CHOP combination therapy. Supporting modules — Drug Response Predictions, Immunoprofile, Flow Cytometry, PARR, MDR1 Genotyping, and Digital Cytology — can be ordered individually or bundled within the PPP, with parallel feline-specific variants of Immunoprofile, Flow Cytometry, and PARR. The xCellSense platform extends the same ex vivo drug sensitivity testing approach to human hematologic cancers (AML, ALL, multiple myeloma, non-Hodgkin lymphoma). The Ex Vivo CRO Services for Pharma arm offers live-cell-based analytics to pharmaceutical companies to accelerate oncology pipelines, and the Veterinary Cancer Pioneers Podcast serves as a brand content channel.

Differentiator

Problem solved

Functional benefit

Brands

  • xCellSense platform: ImpriMed's proprietary platform used for ex vivo drug sensitivity testing combined with genomic profiling to predict clinical responses and identify synergistic drug combinations in oncology research, including acute myeloid leukemia.

Products and services

  • Personalized Prediction Profile (PPP) AI-driven drug response prediction service for canine lymphoma and leukemia that combines live-cell drug sensitivity testing, flow cytometry, and PARR clonality testing with proprietary AI models to predict response to 13 anticancer drugs and CHOP combination therapy. For board-certified veterinary oncologists and their canine patients, with 7-day turnaround.
  • Drug Response Predictions Standalone AI-driven anticancer drug selection service for canine patients using ImpriMed's live-cell drug sensitivity testing platform, providing personalized drug response predictions without the full Immunoprofile component. For veterinary oncologists.
  • Canine Immunoprofile Canine diagnostic support service combining flow cytometry and PARR testing to subtype lymphoma/leukemia and provide prognostic information. For veterinary oncologists.
  • Canine Flow Cytometry Canine flow cytometry service that determines lymphoma or leukemia subtypes by quantifying levels of 10 antigens (CD21, CD79a, CD3, CD4, CD8, CD5, CD45, CD34, CD14, MHC class II) on patient tumor cells. For veterinary oncologists.
  • Canine PARR (PCR for Antigen Receptor Rearrangement) Canine PCR-based clonality test that detects neoplastic B-cell or T-cell clones by amplifying the VJ region of the immunoglobulin heavy chain gene and a region in the T-cell receptor gamma chain gene, helping discriminate lymphoma from reactive or inflammatory conditions. For veterinary oncologists.
  • Multidrug Sensitivity Genotyping (MDR1) Canine genetic test that identifies MDR1 carrier status to predict drug sensitivity and help avoid adverse drug reactions. For veterinary oncologists.
  • Digital Cytology Cytology confirmation service for lymphoma or leukemia diagnosis with digital analysis. For veterinary oncologists.
  • Feline Immunoprofile Feline-specific diagnostic support service combining PARR and flow cytometry for lymphoma/leukemia subtype diagnosis, including cell-sizing data for high-accuracy feline lymphoma characterization. For veterinary oncologists treating feline patients.
  • Feline Flow Cytometry Feline-specific flow cytometry service for accurate lymphoma or leukemia subtype determination. For veterinary oncologists treating feline patients.
  • Feline PARR Feline-specific PCR for Antigen Receptor Rearrangement assay with high-specificity detection of clonal neoplasia and B-cell/T-cell clonality testing, returning cell sizing and immunophenotyping results in 3-4 calendar days. For veterinary oncologists treating feline patients.
  • Ex Vivo CRO Services for Pharma Contract research organization service offering live-cell-based predictive analytics to accelerate pharmaceutical and biotech oncology pipelines, with ex vivo drug sensitivity testing on patient-derived cancer cells across programs such as AML, multiple myeloma, pancreatic cancer, and non-Hodgkin lymphoma. For pharmaceutical and biotechnology companies.
  • Human Precision Medicine (xCellSense Platform) AI-driven precision medicine service for human oncology that uses the xCellSense platform to combine ex vivo drug sensitivity testing with genomic profiling to predict patient-specific drug responses and identify synergistic drug combinations, with research and investigational use in AML, ALL, multiple myeloma, and non-Hodgkin lymphoma. For academic translational researchers, hematologist-oncologists, and pharmaceutical partners.

Companies that use ImpriMed

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

ImpriMed technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

ImpriMed partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered flagship and core.

  • Mayo Clinic PlatformflagshipStrategic or Co-development PartnerImpriMed was one of 7 startups selected for the Mayo Clinic AI Accelerator (per MedCity News 2022 coverage referenced on ImpriMed's homepage). The accelerator supports validation and scaling of ImpriMed's AI platform in a clinical environment.
  • Stripe, Inc.coreTechnology or IntegrationStripe is ImpriMed's third-party payment processor for veterinary clinic transactions; ImpriMed does not store any card payment data, and all Stripe-collected data is subject to Stripe's privacy notice.
  • FedExcoreChannel Partner/ Reseller/ DistributorImpriMed provides prepaid FedEx shipping labels and boxes to veterinary clinics to enable overnight delivery of live tumor and blood samples to its Palo Alto lab; central to the live-cell assay workflow.
  • American Association for Laboratory Accreditation (A2LA)coreOthersA2LA accredits ImpriMed's US laboratory under Certificate #5664.01 for canine lymphoma/leukemia PARR clonality testing, flow cytometry immunophenotyping, MDR1 genotyping, and feline PARR/flow cytometry services.

Scale indicators13 records

Recent moves9 records

Expansion highlights6 records

ImpriMed competitors and assessment

Company assessment

Direct peers

  • FidoCure (One Health Company): FidoCure offers precision medicine and genetic testing for canine cancer, directly overlapping ImpriMed's veterinary oncology positioning. Both companies target veterinary oncologists with AI-driven drug selection tools for dogs with cancer.
  • Vidium Animal Health: Vidium provides precision medicine diagnostics and genomic testing for veterinary cancer patients. It is a direct competitor in the veterinary oncology precision diagnostics space, serving the same board-certified oncologist customer base as ImpriMed.

Emerging players

  • PetDx: PetDx develops liquid biopsy and multi-cancer early detection tests for dogs using next-generation sequencing. While focused on detection rather than drug response prediction, it competes for the same veterinary oncology budget and clinical workflow slot as ImpriMed.
  • Personalis: Personalis provides genomics-based precision oncology services for biopharma and clinicians, with a focus on minimal residual disease and tumor profiling. Comparable to ImpriMed's pharma CRO arm and its planned human oncology expansion via multi-omic AI.
  • Notable Labs: Notable Labs offers ex vivo drug sensitivity testing for cancer patients using automated platforms to predict treatment response. It is a direct comparable to ImpriMed's ex vivo CRO offering and xCellSense platform, especially in hematologic malignancies.
  • Embark Veterinary: Embark provides dog DNA and genetic health testing, including MDR1 and breed-related risk screening. It overlaps with ImpriMed's MDR1 genotyping and precision veterinary positioning but targets a broader pet-owner consumer audience.

Broad incumbents

  • IDEXX Laboratories: IDEXX is the dominant veterinary diagnostics company, offering reference lab services across many species and analytes. It is a broad incumbent whose reference lab and specialty offerings overlap with ImpriMed's veterinary diagnostic services, though IDEXX does not focus specifically on AI-driven oncology drug response prediction.
  • Antech Diagnostics (Mars Petcare): Antech is a large veterinary reference laboratory network owned by Mars Petcare, offering broad diagnostic panels including oncology. It competes with ImpriMed for veterinary clinic reference lab spend, though its AI-driven lymphoma drug response prediction capability is not a comparable focus.
  • Tempus AI: Tempus is a leading human precision medicine company using AI and multi-modal data (genomics, imaging, clinical) to support oncology decision-making. It is relevant as ImpriMed's reference point for scaling its xCellSense human precision medicine platform.
  • Guardant Health: Guardant Health is a leading liquid biopsy and precision oncology company focused on human cancer. It is a broad incumbent relevant to ImpriMed's human oncology roadmap, particularly as a comparator on data scale and pharma partnership economics.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

ImpriMed social profiles

Digital presence

ImpriMed compliance and trust

Trust signal

Compliance5 records

ImpriMed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ImpriMed leadership team

Management profile

Number of profiles

Profiles3 records

ImpriMed subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ImpriMed funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors29 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ImpriMed M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImpriMed

What does ImpriMed do?

ImpriMed provides AI-driven precision medicine services that predict anticancer drug response for individual veterinary and human oncology patients. Its core offering is a laboratory-based diagnostic and predictive service (centered on the Personalized Prediction Profile) that combines live-cell drug sensitivity testing, flow cytometry, and PARR clonality testing with proprietary multimodal AI models trained on thousands of real-world canine patient outcomes. The company also sells contract research services (Ex Vivo CRO Services for Pharma) using its xCellSense platform to accelerate pharmaceutical oncology pipelines.

Is ImpriMed a public or private company?

ImpriMed is a private company. It is classified as venture growth investor backed and is currently operating.

When was ImpriMed founded?

ImpriMed was founded in 2017. It employs 11 to 50 people.

Where is ImpriMed based?

ImpriMed is headquartered in Palo Alto, United States, in the North America region.

How does ImpriMed make money?

Three revenue lines are on record. Per-test veterinary service fees are the primary driver. The others are ex vivo CRO services for pharma and biotech and human precision medicine research services.

Who are ImpriMed's main competitors?

Direct peers on record are FidoCure (One Health Company) and Vidium Animal Health. Emerging players are PetDx, Personalis, Notable Labs and Embark Veterinary. Broad incumbents are IDEXX Laboratories, Antech Diagnostics (Mars Petcare), Tempus AI and Guardant Health.

Does ImpriMed have an API?

No public API is recorded for ImpriMed.

What industry is ImpriMed in?

ImpriMed's product category is Veterinary Diagnostics. Its primary akta.pro industry code is HLAMADAA, Reference Laboratory Testing (Clinical Pathology & Chemistry), with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 54194 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsImpriMed Raises $10M in Series A2 Bridge FundingImpriMed, a Seoul-based precision medicine company, raised $10M in Series A2 bridge funding led by LB Investment. The funds will advance U.S. commercialization and expand into Asia, with FDA clearance and CLIA certification targeted for Q1 2027.AipressroomImpriMed Raises $10M to Expand Precision MedicineImpriMed raised $10M in a Series A2 bridge round led by LB Investment to commercialize AI-driven cancer diagnostics in the U.S. and expand globally. The capital will fund U.S. commercialization and international expansion, with FDA clearance and CLIA certification by Q1 2027.YahooNAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMedNAVER D2SF invested in ImpriMed, a precision medicine company, joining its $10 million Series A2 bridge round. ImpriMed's AI-driven platform combines ex vivo cell analysis with genomic and clinical data to guide personalized cancer treatment. The company plans U.S. commercialization by Q1 2027 and has an approved Korean software for multiple myeloma.PR NewswireNAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMedNAVER D2SF invested in ImpriMed, a precision medicine company, joining its $10 million Series A2 bridge round. ImpriMed combines ex vivo functional testing with AI to support personalized cancer treatment decisions. The company plans to commercialize products for blood cancers and infections, targeting FDA clearance and CLIA certification by Q1 2027.BiggoNAVER's Venture Capital Arm Invests in U.S. AI Precision Medicine Startup ImpriMed — BigGo FinanceNAVER D2SF invested in ImpriMed, a U.S. AI precision medicine startup, in its $10 million Series A2 bridge round. ImpriMed plans FDA clearance and CLIA certification by Q1 2027, targeting blood cancers. The company has completed over 27,000 veterinary oncology tests.Masters-Of-LongevityNAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMedNAVER D2SF invested in ImpriMed as part of a $10 million Series A2 bridge round. ImpriMed trains AI on over 3.5 million data points from ex vivo cell tests and genomic/clinical data. The company targets FDA clearance and CLIA certification for U.S. commercialization.MarketScreenerImpriMed, Inc. announced that it has received $10.000002 million in funding from Alois Ventures, BonAngels Venture Partners, Inc., Han River Development LLC, LB Investment Inc., Samsung Securities Limited, NAVER D2 Startup FactoryImpriMed, Inc. closed a $10,000,002 Series A-3 financing on September 18, 2026, issuing 4,060,090 shares at $2.463 each. The round was led by LB Investment Inc. with participation from Alois Ventures, Samsung Securities, NAVER D2 Startup Factory, and returning investors BonAngels and Han River Development.Business Wire BlogImpriMed CEO Dr. Sungwon Lim Invited to National Cancer Institute Panel on Commercializing Functional Precision MedicineImpriMed CEO Dr. Sungwon Lim has been invited by the National Cancer Institute to serve as a panelist at a functional precision medicine workshop in July 2026, joining representatives from Tempus AI, Travera, Exvivo Labs, First Ascent Biomedical, KYAN Technologies, and Cancer Commons. The workshop, convened by the NCI's Division of Cancer Treatment and Diagnosis, aims to accelerate the translation of functional precision medicine from research into clinical and commercial use. ImpriMed, which has processed over 15,000 patient cancer cell samples and operates CRO services for pharmaceutical drug development, cited this as recognition of its leadership role in the growing field.Grand View ResearchVeterinary Precision Medicine Market Size Report, 2026-2033The global veterinary precision medicine market was valued at $558.9 million in 2025 and is projected to grow to $1.5 billion by 2033, at a CAGR of 13.5%, driven by rising companion animal cancer prevalence, pet humanization trends, and AI/ML advances in bioinformatics. North America held the largest regional share at 44.6% in 2025, with the diagnostic and pathology segment commanding 39.3% of market revenue and oncology representing the dominant therapeutic area. Key market participants including ImpriMed, FidoCure, Anivive Lifesciences, PetDx, LEAH Labs, and Elias Animal Health are expanding AI-driven drug response prediction, genomic profiling, and cell therapy services, with Asia Pacific identified as the fastest-growing region for companion animal precision oncology.Business Wire BlogMedTech Innovator Asia Pacific Selects Top 20 Startups for 2026 APAC Accelerator Program from 680+ ApplicantsMedTech Innovator Asia Pacific selected 20 startups from over 680 applicants for its 2026 APAC Accelerator Program, representing the top 3% of applicants. The cohort will run from June to October 2026, with a final in Singapore where companies compete for up to $275,000 in cash prizes.